Posted by admin on Apr 30, 2016 in |
Hyperlipidemia is a common finding in uncontrolled Diabetes Mellitus (DM) and patients with DM generally show alteration in lipid profile, notably in triglycerides value. Research done in the past has pointed out the usefulness of Atherogenic Index of Plasma (AIP) as a useful parameter for the diagnosis of Type 2 DM. HbA1c is well established as gold standard to monitor long term diabetic control. Further elevated lipid profile markers have been linked to a host of diseases like Cardiovascular, liver and kidney. Some studies have shown reasonable association between AIP to plasma glucose and HbA1c, but this study did not find any association between AIP to HbA1c and glucose, but very good association have been observed between Atherogenic ratio to both plasma glucose and HbA1c suggesting that lipid profile test to be made as routine for the diagnostic improvement of all DM patients. The contents of this study will serve as a model for future researchers to explore more studies in this field to define a set of diagnostic...
Read More
Posted by admin on Apr 30, 2016 in |
The aim of this research is to precisely discuss and appraise the success of different approaches to the development to antiplatelet drugs. Platelets play a main function in haemostasis and the development of arterial thrombosis that is the final event complicating cardiovascular diseases and peripheral vascular diseases, and antiplatelet drugs improve survival of patients with these diseases. Antiplatelet drugs are aimed to avert and/or reverse platelets aggregation in arterial thrombosis, most significantly in myocardial infarction (MI), ischaemic stroke, and peripheral artery disease. The current therapeutic strategies aimed at inhibiting platelet aggregation: inhibition of cyclooxygenase, such as aspirin; inhibition of phosphodiesterases III and V and adenosine uptake by red blood cells, such as dipyridamole and cilostazol; inhibition of the platelet adenosine diphosphate (ADP) P2Y12 receptor, such as ticlopidine and clopidogrel; inhibition of glycoprotein IIb/IIIa receptors that prevent fibrinogen binding, such as abciximab; and increasing nitric oxide level, such as triflusal. A range of new drugs are currently in different phases of clinical trials, including reloading of clopidogrel, the improvement of...
Read More
Posted by admin on Apr 30, 2016 in |
Jivanti is considered a stimulant and tonic in Ayurvedic literature. Its medicinal use dates back to about 4500 to 1600 BC, as mentioned in classical texts. Holostemma ada- kodien and Leptadenia reticulata are the two plants used in Ayurveda as source plants of the drug Jivanti. Roots of these plants are used in several Ayurvedic preparations. Though Ayurvedic Formulary of India mentions Leptadenia reticulata as the source plant of Jivanti, throughout Kerala and mostly in South India, Holostemma ada- kodien is used as source plants of Jivanti and there are reports regarding adulteration in market samples, which will adversely affect the quality of medicines prepared. Till now there is no significant study to compare the source plants available in markets as Jivanti. Present work is a comparative histological, histochemical and phytochemical study of the raw drug Jivanti from different raw drug markets of Kerala. This is a first time approach to develop quality control measures with the help of histological, histochemical and phytochemical...
Read More
Posted by admin on Apr 30, 2016 in |
The present study was taken to prove the cytotoxic effect of ethanolic extract of Gmelina asiatica leaf on human breast cancer cell line MCF-7. The in vitro cytotoxicity was evaluated by performing MTT assay. Cell morphological characteristics were observed by using phase contrast microscope. The results demonstrated in MCF-7 cancer cell lines treated with ethanolic extract of G. asiatica leaf showed the cell death which is dose dependent. Only 8.2 % of cell viability was observed at 1000µg/ml concentration of G. asiatica leaf extract. It is concluded that the ethanolic extract of Gmelina asiatica leaf can be used for the treatment of breast...
Read More
Posted by admin on Apr 30, 2016 in |
Objective: To observe the variations in levels of serum amylase and serum lipase, in patients with type 2 DM after treatment with DPP-4 inhibitors. METHODS: Under this study, 174 Type 2 diabetes mellitus patients were analysed for variations in levels of exocrine pancreatic enzymes after use of dipeptidyl peptidase (DPP) 4 inhibitors. The effect was compared with those under treatment with other oral hypoglycaemic agents. Cases included in the study (n=90) were patients of type 2 diabetes mellitus on gliptins ± other oral hypoglycemic drugs. The control (n=84) included age and sex matched subjects, treated with other antihyperglycemic agents other than gliptins. Serum amylase and serum lipase levels were monitored at baseline, 3monthly and 6 monthly intervals. Results: Mean serum amylase levels in cases as compared to controls at 3 and 6 monthly intervals were 61.38±14.35U/L;94.57 ± 22.99U/L and 43.34± 9.80U/Land 45.72 ±8.40 U/L respectively. Difference between two groups was statistically significant at both time intervals. Similarly mean serum lipase levels in cases as compared to controls at 3...
Read More
